ApicHope Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
ApicHope Pharmaceutical has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 12.4% per year. ApicHope Pharmaceutical's return on equity is 5.3%, and it has net margins of 7.2%.
Key information
8.3%
Earnings growth rate
8.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 12.4% |
| Return on equity | 5.3% |
| Net Margin | 7.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How ApicHope Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,410 | 174 | 1,294 | 316 |
| 31 Dec 23 | 2,503 | 185 | 1,453 | 301 |
| 30 Sep 23 | 2,515 | 307 | 1,488 | 249 |
| 30 Jun 23 | 2,641 | 341 | 1,624 | 250 |
| 31 Mar 23 | 2,480 | 322 | 1,564 | 204 |
| 31 Dec 22 | 2,280 | 291 | 1,458 | 190 |
| 30 Sep 22 | 2,161 | 285 | 1,405 | 160 |
| 30 Jun 22 | 2,151 | 344 | 1,410 | 160 |
| 31 Mar 22 | 2,200 | 319 | 1,446 | 150 |
| 31 Dec 21 | 2,199 | 307 | 1,448 | 142 |
| 30 Sep 21 | 2,135 | 317 | 1,388 | 169 |
| 30 Jun 21 | 1,978 | 263 | 1,273 | 149 |
| 31 Mar 21 | 1,851 | 250 | 1,169 | 146 |
| 31 Dec 20 | 1,675 | 226 | 1,037 | 135 |
| 30 Sep 20 | 1,640 | 173 | 1,009 | 111 |
| 30 Jun 20 | 1,515 | 117 | 947 | 96 |
| 31 Mar 20 | 1,641 | 138 | 1,006 | 90 |
| 31 Dec 19 | 1,637 | 144 | 985 | 98 |
| 30 Sep 19 | 1,537 | 243 | 847 | 87 |
| 30 Jun 19 | 1,435 | 234 | 764 | 101 |
| 31 Mar 19 | 1,395 | 219 | 727 | 102 |
| 31 Dec 18 | 1,430 | 208 | 708 | 91 |
| 30 Sep 18 | 1,426 | 180 | 666 | 97 |
| 30 Jun 18 | 1,477 | 167 | 592 | 112 |
| 31 Mar 18 | 1,467 | 166 | 548 | 94 |
| 31 Dec 17 | 1,380 | 157 | 514 | 81 |
| 30 Sep 17 | 1,399 | 156 | 539 | 41 |
| 31 Dec 16 | 1,251 | 137 | 479 | 0 |
| 31 Dec 15 | 1,028 | 60 | 436 | 0 |
| 31 Dec 14 | 793 | 40 | 319 | 0 |
| 31 Dec 13 | 508 | 33 | 134 | 0 |
Quality Earnings: 300723 has high quality earnings.
Growing Profit Margin: 300723's current net profit margins (7.2%) are lower than last year (13%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300723's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: 300723's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300723 had negative earnings growth (-46%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.01%).
Return on Equity
High ROE: 300723's Return on Equity (5.3%) is considered low.